Broken String Biosciences launches BaseMap ABE to enable genome-wide off-target characterization in base editing therapeutic development

Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today announced the launch of BaseMap^™ ABE. Built on the Company\'s INDUCE-seq^® technology, BaseMap ABE extends the platform\'s capabilities to support adenine base editing (ABE) applications.

Base editing is rapidly gaining momentum as a powerful therapeutic tool that enables precise single-base genomic changes. However, as therapeutic programs increasingly adopt ABE, researchers require reproducible and standardized methods to comprehensively characterize unintended off-target editing events.

Unlike prediction-based approaches, BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with clear understanding of editor specificity under physiologically relevant conditions. The platform enables rapid, unbiased identification of off-target events, while generating standardized and robust data to support guide optimization, editor selection and preclinical decision making.

BaseMap ABE represents the first phase of Broken String Biosciences' expansion into base editing applications, building on its established INDUCE-seq technology. Through the Early Access Program, the Company will collaborate closely with researchers developing genome editing therapies, providing first-hand experience for early adopters and generating feedback to inform future product development.

As gene editing technologies evolve, researchers need to wholly understand where and how frequently off-target editing occurs. By extending our product portfolio to support ABE, Broken String is enabling scientists to characterize editing outcomes for one of the most promising next-generation editing modalities. We are excited to get this solution into the hands of early-adopters - working closely with them to shape the future of our product and support the development of safe and effective base editing therapeutics."

Terry Pizzie, CEO, Broken String Biosciences